Olanzapine-associated neuroleptic malignant syndrome: Is there an overlap with the serotonin syndrome?
Tóm tắt
The neuroleptic malignant syndrome is a rare but serious condition mainly associated with antipsychotic medication. There are controversies as to whether "classical" forms of neuroleptic malignant syndrome can occur in patients given atypical antipsychotics. The serotonin syndrome is caused by drug-induced excess of intrasynaptic 5-hydroxytryptamine. The possible relationship between neuroleptic malignant syndrome and serotonin syndrome is at present in the focus of scientific interest. This retrospective phenomenological study aims to examine the seventeen reported olanzapine – induced neuroleptic malignant syndrome cases under the light of possible overlap between neuroleptic malignant syndrome and serotonin syndrome clinical features. The serotonin syndrome clinical features most often reported in cases initially diagnosed as neuroleptic malignant syndrome are: fever (82%), mental status changes (82%) and diaphoresis (47%). Three out of the ten classical serotonin syndrome clinical features were concurrently observed in eleven (65%) patients and four clinical features were observed in seven (41%) patients. The results of this study show that the clinical symptoms of olanzapine-induced neuroleptic malignant syndrome and serotonin syndrome are overlapping suggesting similarities in underlying pathophysiological mechanisms.
Tài liệu tham khảo
Caroff SN, Mann SC: Neuroleptic malignant syndrome. Med Clin North Am. 1993, 77: 185-202.
Bobolakis I: Neuroleptic malignant syndrome after antipsychotic drug administration during benzodiazepine withdrawal. J Clin Psychopharmacol. 2000, 20: 281-283. 10.1097/00004714-200004000-00033.
Sachdev P, Kruk J, Kneebone M, Kissane D: Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol. 1995, 15: 365-371. 10.1097/00004714-199510000-00010.
Karagianis JL, Phillips LC, Hogan KP, Le Drew KL: Clozapine-associated neuroleptic malignant syndrome: two new cases and review of the literature. Ann Pharmacother. 1999, 33: 623-630.
Caroff SN, Mann SC, Campbell EC: Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatr Ann. 2000, 30: 314-321.
Srernbach H: The serotonin syndrome. Am J Psychiatry. 1991, 148: 705-713.
Nimmagadda SR, Ryan DH, Atkin SL: Neuroleptic malignant syndrome after venlafaxine. Lancet. 2000, 365: 289-290. 10.1016/S0140-6736(99)03514-X.
Martin TG: Serotonin syndrome. Ann Emerg Med. 1996, 28: 520-526.
Martin J, Gomez JC, Garcia-Bernardo E, Cuesta M, Alvarez E, Gurpegui M: Olanzapine in treatment refractory schizophrenia: results of an open-label study. J Clin Psychiatry. 1997, 58: 479-483.
Johnon V, Bruxner G: Neuroleptic malignant syndrome associated with olanzapine. Aust NZJ Psychiatry. 1998, 32: 884-886.
Filice GA, Mc Dougall BC, Ercan-Fang N, Billington CJ: Neuroleptic malignant syndrome associated with olanzapine. An Pharmacother. 1998, 32: 1158-1159.
Moltz DA, Coeytaux RR: Case report: possible neuroleptic malignant syndrome associated with olanzapine. J Clin Psychopharmacol. 1998, 18: 485-486. 10.1097/00004714-199812000-00014.
Hanel RA, Sandmann MC, Kranich M, De Bittencourt PRM: Neuroleptic malignant syndrome: case report of a recurrence related to olanzapine. Arq Neuropsychiatr. 1998, 56: 833-837.
Burkhard PR, Vingerhoets FJG, Alberque C, Landis T: Olanzapine-induced neuroleptic malignant syndrome. Arch Gen Psychiatry. 1999, 56: 101-102. 10.1001/archpsyc.56.1.101.
Emborg C: Neuroleptic malignant syndrome after treatment with olanzapine. Ugeskz Laeger. 1999, 161: 1424-1425.
Apple JE, Van Hauser G: Neuroleptic malignant syndrome associated with olanzapine therapy [letter]. Psychosomatics. 1999, 40: 267-268.
Hickey C, Stewart C, Lippmann S: Olanzapine and NMS. Psychiatr Services. 1999, 50: 836-837.
Margolese HC, Chouinard G: Olanzapine-induced neuroleptic malignant syndrome with mental retardation. Am J Psychiatry. 1999, 156: 1115-1116.
Garcia Lopez MM, Cipres L, de Centra E, Vilalta Franch J: Neuroleptic malignant syndrome associated with olanzapine. Med Clin (Barcelona). 1999, 113: 239-
Levenson JL: Neuroleptic malignant syndrome after the initiation of olanzapine. J Clin Psychopharmacol. 1999, 19: 477-478. 10.1097/00004714-199910000-00016.
Georghiou S, Knobler HY, Drumer D: Recurrence of neuroleptic malignant syndrome with olanzapine treatment. Am J Psychiatry. 1999, 156: 1836-
Hagarty JM, Husni M, Peat C, Allain S: Atypical neuroleptic malignant syndrome?. Can J Psychiatry. 1999, 44: 711-712.
Nyfort-Hansen K, Alderman CP: Possible neuroleptic malignant syndrome associated with olanzapine. An Pharmacother. 2000, 34: 667-10.1345/aph.19239.
Jarventausta K, Leinonen E: Neuroleptic malignant syndrome during olanzapine and levopromazine treatment. Acta Psychiatr Scand. 2000, 102: 231-233. 10.1034/j.1600-0447.2000.102003231.x.
Stanfield SC, Privette T: Neuroleptic malignant syndrome associated with olanzapine therapy: a case report. J Emerg Med. 2000, 19: 355-357. 10.1016/S0736-4679(00)00263-8.
Sierra-Biddle D, Herran A, Diez-Aja S, Gonzalez-Mata JM, Vidal E, Diez-Manrique F, Vaquez-Barquero JL: Neuroleptic malignant syndrome and olanzapine. J Clin Psychopharmacol. 2000, 20: 704-705. 10.1097/00004714-200012000-00021.
Kontaxakis VP, Havaki-Kontaxaki BJ, Christodoulou NG, Paplos KG: Olanzapine-associated neuroleptic malignant syndrome. Progr Neuropsychopharmacol Biol Psychiatry. 2002, 26: 897-902. 10.1016/S0278-5846(02)00202-6.
Nisijima K: Abnormal monoamine metabolism in celebrospinal fluid in a case of serotonin syndrome. J Clin Psychopharmacol. 2000, 20: 107-108. 10.1097/00004714-200002000-00022.
Fink M: Toxic serotonin syndrome or neuroleptic malignant syndrome. Pharmacopsychiatry. 1996, 29: 159-161.